HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Watkinson, J. C. Articles by Clarke, S. E. Search for Related Content PubMed PubMed Citation Articles by Watkinson, J. C. Articles by Clarke, S. E.

Technetium-99m (v) Dimercaptosuccinic Acid Uptake in Patients with Head and Neck Squamous Carcinoma: Experience in Imaging

Departments of Nuclear Medicine and Otolaryngology, Guy's Hospital, London, UK

Correspondence: For reprints contact: John C. Watkinson, Dept. of Nuclear Medicine, Guy's Hospital, St. Thomas' St., London SE1 9RT.

ABSTRACT

A recently developed imaging agent, technetium-99m (v) dimercaptosuccinic acid (^99mTc (v) DMSA), has been used to assess head and neck squamous carcinoma (SCC). We have prospectively studied 62 patients of whom 53 had a histologically proven head and neck SCC. The remaining nine had benign lesions. The results of planar imaging in patients with primary disease yielded an 85% sensitivity and 78% specificity. Planar imaging in patients with cervical lymphadenopathy revealed a 59% sensitivity. Nineteen patients also had single photon emission computed tomography imaging which improved the image quality, spatial resolution and sensitivity of the investigation. Twenty-seven patients were scanned before and after radiotherapy and, of these, 96% showed positive uptake in the salivary glands with no evidence of tumor recurrence. This study has shown ^99mTc (v) DMSA imaging provides a cheap and rapid method of investigating head and neck SCC and further studies are necessary to evaluate its role in the management of patients with this disease.